Table 1.
Mutational profiling of 446 melanomas
| Melanoma | Negative | BRAF | HRAS | KRAS | NRAS | KIT | PIK3CA |
|---|---|---|---|---|---|---|---|
| Uveal (n = 2) | 2 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Mucosal (n = 20) | 12 (60%) | 1 (5.0%) | 0 (0%) | 1 (5.0%) | 4 (20%) | 3 (15%) | 1 (5.0%) |
| Cutaneous (n = 286)a | 72 (25%) | 132 (46%) | 9 (3.1%) | 7 (2.4%) | 64 (22%) | 14 (4.9%) | 6 (2.1%) |
| Others (n = 138)b | 32 (23%) | 56 (41%) | 0 (0%) | 4 (2.9%) | 42 (30%) | 5 (3.6%) | 5 (3.6%) |
| Total (n = 446)a | 118 (26%) | 189 (42%) | 9 (2.0%) | 12 (2.7%) | 110 (25%) | 22 (4.9%) | 12 (2.7%) |
a11 specimens with no mutation detected and an estimated tumor cellularity of less than 10% were excluded
bMetastatic melanomas of unknown origin or without information of the primary site